VG 3927
Alternative Names: VG-3927Latest Information Update: 16 Jan 2024
At a glance
- Originator Vigil Neuroscience
- Class Antidementias; Neuroprotectants; Small molecules
- Mechanism of Action TREM2 protein-stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 06 Oct 2023 Phase-I clinical trials in Alzheimer's disease (In volunteers) (PO) (Vigil Neurosciences pipeline, October 2023) (NCT06343636)
- 06 Oct 2023 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Alzheimer's disease released by Vigil Neurosciences
- 08 Sep 2023 US FDA approves IND application for VG 3927 in Alzheimer's disease with partial hold on maximum exposure limit